Shaanxi Kanghui Pharmaceutical Co., Ltd. Shaanxi Kanghui Pharmaceutical Co., Ltd. (603139.SS) engages in the research, development, production, and sale of pharmaceutical products primarily in China. Founded in 1999 and headquartered in Xianyang, Shaanxi Province, the company manufactures a diverse portfolio of proprietary Chinese medicines and other drugs targeting gynecological, orthopedic, dermatological, diabetes, respiratory system, urinary system, cardiovascular and cerebrovascular, gastrointestinal, hepatobiliary, and tranquilizer conditions; these are offered in forms including tablets such as Compound Double Flower Tablets, capsules like Kunfukang Capsules and Cinnamon Bone Pain Capsules, granules including Silver Eliminating Granules and Astragalus Medicine Thirst Quenching Granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. It also conducts pharmaceutical distribution encompassing wholesale of biologics, blood products, pharmaceuticals, and Chinese herbal medicines, alongside involvement in Chinese medicine tablets and chemical intermediates. The company, which completed shareholding system reform in 2009 and listed on the Shanghai Stock Exchange main board in April 2017, operates as a national high-tech enterprise with wholly-owned and holding subsidiaries in drug distribution, medical devices, and private equity funds. Recent developments include the agreement to acquire a 51% stake in Shaanxi Xingaoxin Pharmaceutical Co., Ltd., enhancing its product portfolio and strategic positioning in the competitive Chinese pharmaceutical market.